MM
Haematology · 2006–2026
71decisions
16medicines
44carried consumer input
2,582individual submissions
Every decision
| Medicine | Meeting | Outcome | Consumer input |
|---|---|---|---|
| teclistamab Treatment of adult patients with relapsed or refractory multiple myeloma (RRMM) who have received at least 3 prior lines of therapy, including a proteasome… | Mar 2026 | Recommended with restriction | 257 individuals Myeloma Australia · Rare Cancers Australia · Leukaemia Foundation · Integrated Clinical Oncology Network |
| daratumumab Treatment of transplant ineligible, newly diagnosed multiple myeloma (TI NDMM) in combination with lenalidomide and dexamethasone. | Mar 2025 | Recommended with restriction | 244 individuals Myeloma Australia · Rare Cancers Australia · Leukaemia Foundation |
| elranatamab Treatment of patients with relapsed or refractory multiple myeloma who have received at least three prior lines of therapy, including a proteasome inhibitor,… | Dec 2025 | Recommended with restriction | 177 individuals Myeloma Australia · Leukaemia Foundation · Rare Cancers Australia |
| belantamab mafodotin Relapsed and/or refractory multiple myeloma (RRMM) after one prior line of therapy, in combination with bortezomib and dexamethasone. | Nov 2025 | Not recommended | 19 individuals |
| elranatamab Treatment of adult patients with relapsed or refractory multiple myeloma who have received at least 3 prior therapies including a proteasome inhibitor, an… | Jul 2024 | Not recommended | 14 individuals Myeloma Australia · Leukaemia Foundation · Rare Cancers Australia |
| pomalidomide Treatment of multiple myeloma in patients requiring dose adjustments (interruptions and reductions) due to haematological toxicities. | Jul 2023 | Recommended | input received Rare Cancers Australia |
| daratumumab Treatment of transplant ineligible, newly diagnosed multiple myeloma in combination with lenalidomide and dexamethasone. | Mar 2023 | Not recommended | 100 individuals Myeloma Australia |
| lenalidomide Multiple myeloma (newly diagnosed, progressive, and relapsed/refractory) and myelodysplastic syndrome, in various monotherapy and combination regimens. | Nov 2023 | Recommended with restriction | input received Rare Cancers Australia |
| bortezomib Multiple myeloma. The submission requested listing of two new solution forms (2.5 mg/mL and 3.5 mg/1.4 mL) under the same circumstances as currently listed… | Mar 2022 | Recommended | 9 individuals |
| bortezomib Multiple myeloma. The submission requested listing of two new solution formulations (2.5 mg/mL and 3.5 mg/1.4 mL) under the same circumstances as currently… | Mar 2022 | Recommended | 9 individuals |
| carfilzomib Treatment of relapsed or refractory multiple myeloma (RRMM) in combination with lenalidomide and dexamethasone after at least one prior therapy. | Mar 2022 | Recommended with restriction | 12 individuals Myeloma Australia · Leukemia Foundation |
| ixazomib Relapsed and/or refractory multiple myeloma (RRMM) after at least two prior therapies, in combination with lenalidomide and dexamethasone. | Mar 2022 | Not recommended | 10 individuals Myeloma Australia · Leukemia Foundation |
| selinexor Treatment of adult patients with relapsed and/or refractory multiple myeloma (RRMM) who have received at least one prior therapy, in combination with… | Mar 2022 | Not recommended | 11 individuals Myeloma Australia · Leukaemia Foundation · Leukemia Foundation |
| selinexor Treatment of adult patients with relapsed and/or refractory multiple myeloma (RRMM) who have received at least four prior lines of therapy and whose disease is… | Mar 2022 | Recommended with restriction | 6 individuals Myeloma Australia |
| selinexor Treatment of adult patients with relapsed and/or refractory multiple myeloma (RRMM) who have received at least one prior therapy, in combination with… | Nov 2022 | Recommended with restriction | 64 individuals Myeloma Australia · Leukaemia Foundation · Leukemia Foundation |
| bortezomib Multiple myeloma (new 2.5 mg vial size for patients requiring doses between 2 mg and 2.5 mg). | Jul 2021 | Recommended with restriction | 10 individuals |
| bortezomib Multiple myeloma (new 2.5 mg vial size for existing PBS-listed indications including previously untreated and previously treated multiple myeloma). | Jul 2021 | Recommended with restriction | 11 individuals |
| daratumumab Relapsed or refractory multiple myeloma (second-line treatment) in combination with bortezomib and dexamethasone. | Jul 2021 | Recommended with restriction | 38 individuals Myeloma Australia · Leukaemia Foundation |
| elotuzumab Treatment of relapsed or refractory multiple myeloma (RRMM) in patients who have received at least one prior therapy, administered in combination with… | Jul 2021 | Recommended with restriction | 20 individuals Myeloma Australia · Leukaemia Foundation · Rare Cancers Australia |
| selinexor Treatment of relapsed and/or refractory multiple myeloma (RRMM) in combination with bortezomib and dexamethasone in adult patients who have received at least… | Jul 2021 | Not recommended | 18 individuals Myeloma Australia · Rare Cancers Australia · Leukaemia Foundation |
| selinexor Treatment of adult patients with relapsed and/or refractory multiple myeloma (RRMM) who have received at least four prior therapies and whose disease is… | Jul 2021 | Not recommended | 3 individuals Myeloma Australia · Rare Cancers Australia · Leukaemia Foundation |
| carfilzomib Addition of a 70 mg/m² once weekly dosing regimen to the existing 56 mg/m² twice weekly regimen for use in combination with dexamethasone in patients with… | Jul 2020 | Recommended with restriction | 37 individuals Myeloma Australia · Leukaemia Foundation · South-East Myeloma Support Group |
| daratumumab Second-line treatment for patients with relapsed and/or refractory multiple myeloma, in combination with bortezomib and dexamethasone. | Jul 2020 | Recommended with restriction | 99 individuals Leukaemia Foundation · Myeloma Australia · South East Myeloma Support Group |
| plitidepsin Treatment of relapsed/refractory multiple myeloma (RRMM) in patients refractory to a proteasome inhibitor (PI) and an immunomodulatory drug (IMiD) in the… | Mar 2020 | Not recommended | 49 individuals Myeloma Australia · Leukaemia Foundation · South East Myeloma Support Group · Rare Cancers Australia · National Institute |
| elotuzumab Treatment of relapsed and/or refractory multiple myeloma (RRMM) in combination with lenalidomide and dexamethasone in patients with progressive disease after… | Nov 2020 | Not recommended | input received Myeloma Australia · Scientific Group · Leukaemia Foundation · Rare Cancers Australia |
| ixazomib Relapsed and/or refractory multiple myeloma (RRMM) in patients who have experienced disease progression with at least one prior therapy, in combination with… | Nov 2020 | Not recommended | 38 individuals Myeloma Australia · Scientific Group · Leukaemia Foundation · Rare Cancers Australia |
| lenalidomide Treatment of patients with newly diagnosed multiple myeloma (NDMM) who are ineligible for an autologous stem cell transplant (ASCT), in combination with… | Aug 2019 | Recommended with restriction | 27 individuals Leukaemia Foundation · Myeloma Australia |
| denosumab Treatment of patients with multiple myeloma who have renal impairment (creatinine clearance ≤60 mL/min). | Jul 2019 | Not recommended | 25 individuals Myeloma Australia · Leukaemia Foundation |
| lenalidomide Maintenance treatment in patients with newly diagnosed multiple myeloma (NDMM) who have undergone an autologous stem cell transplant (ASCT). | Jul 2019 | Deferred | 75 individuals |
| plitidepsin Treatment of relapsed/refractory multiple myeloma (RRMM) in patients who are refractory to a proteasome inhibitor (PI) and an immunomodulatory drug (IMiD) in… | Jul 2019 | Not recommended | 32 individuals Both Myeloma Australia · Leukaemia Foundation |
| pomalidomide Treatment of patients with relapsed or refractory multiple myeloma (RRMM) who have undergone or are ineligible for a stem cell transplant, and who have… | Jul 2019 | Not recommended | 33 individuals Leukaemia Foundation |
| daratumumab Relapsed or refractory multiple myeloma (RRMM) in combination with bortezomib and dexamethasone for patients who had failed at least one prior therapy, and as… | Mar 2019 | Not recommended | input received Leukaemia Foundation · Myeloma Australia · Scientific Group |
| lenalidomide Maintenance treatment in patients with newly diagnosed multiple myeloma (NDMM) who have undergone an autologous stem cell transplant (ASCT). | Mar 2019 | Deferred | 107 individuals Leukaemia Foundation · Myeloma Australia |
| lenalidomide Amendment of PBS restriction level from Authority Required (Written) to Authority Required (STREAMLINED) for existing listings in newly diagnosed multiple… | Mar 2019 | Not recommended | 51 individuals Leukaemia Foundation · Myeloma Australia |
| daratumumab Relapsed or refractory multiple myeloma (RRMM) in combination with bortezomib and dexamethasone in patients who have received one prior line of therapy… | Nov 2019 | Deferred | 89 individuals Leukaemia Foundation · Myeloma Australia · Rare Cancers Australia · South East Myeloma Support Group |
| pomalidomide Treatment of patients with relapsed or refractory multiple myeloma (RRMM) who have undergone or are ineligible for a stem cell transplant (SCT), and who have… | Nov 2019 | Recommended with restriction | 52 individuals Leukaemia Foundation · Myeloma Australia · South East Myeloma Support Group |
| denosumab Prevention of skeletal-related events in patients with multiple myeloma and bone lesions. | Jul 2018 | Not recommended | 96 individuals Myeloma Australia |
| zoledronic acid Treatment of multiple myeloma, bone metastases from breast cancer or castration-resistant prostate cancer, and hypercalcaemia of malignancy. | Jul 2018 | Recommended with restriction | no section in document |
| carfilzomib Treatment of patients with multiple myeloma who have failed at least one prior line of treatment, in combination with dexamethasone. | Mar 2018 | Recommended | none received |
| lenalidomide Maintenance therapy in patients with newly diagnosed multiple myeloma who have undergone an autologous stem cell transplant (ASCT). | Mar 2018 | Not recommended | 199 individuals Myeloma Australia · South East Myeloma Support Group |
| pomalidomide Multiple myeloma in relapsed/refractory patients who have failed lenalidomide and a proteasome inhibitor (bortezomib or carfilzomib), in combination with… | Nov 2018 | Not recommended | none received |
| denosumab Prevention of skeletal related events in patients with multiple myeloma. | Nov 2018 | Not recommended | none received |
| carfilzomib Treatment of relapsed or refractory multiple myeloma (RRMM) after ≥1 prior therapy in combination with dexamethasone. | Jul 2017 | Recommended with restriction | 75 individuals Myeloma Australia |
| pomalidomide Treatment of patients with relapsed and refractory multiple myeloma who have experienced severe intolerance or toxicity to lenalidomide and/or bortezomib. | Mar 2017 | Not recommended | input received |
| daratumumab Treatment of relapsed or refractory multiple myeloma (RRMM) in combination with bortezomib and dexamethasone or lenalidomide and dexamethasone, in patients… | Nov 2017 | Not recommended | 123 individuals Myeloma Australia |
| lenalidomide Extension of listing to remove the requirement for thalidomide trial prior to lenalidomide use, and to allow retreatment with lenalidomide in relapse or… | Nov 2017 | Recommended with restriction | no section in document |
| pomalidomide Treatment of patients with relapsed and refractory multiple myeloma who have experienced severe intolerance or toxicity to lenalidomide and/or bortezomib. | Nov 2017 | Noted | none received |
| bortezomib Multiple myeloma: newly diagnosed patients (ineligible for and eligible for high-dose chemotherapy with autologous stem cell transplantation) and relapsed… | Mar 2016 | Recommended with restriction | none received |
| lenalidomide First-line therapy in the treatment of patients with newly diagnosed symptomatic multiple myeloma who are ineligible for stem cell transplant. | Mar 2016 | Recommended with restriction | no section in document |
| pomalidomide Treatment of patients with relapsed and refractory multiple myeloma who have experienced treatment failure with lenalidomide and/or bortezomib. | Mar 2016 | Not recommended | none received |
| carfilzomib Treatment of relapsed or refractory multiple myeloma in patients who have received at least one prior therapy. | Nov 2016 | Not recommended | 168 individuals |
| lenalidomide Treatment of newly diagnosed symptomatic multiple myeloma (NDMM) in patients ineligible for stem cell transplantation, given in combination with dexamethasone. | Nov 2015 | Deferred | input received |
| pomalidomide Treatment of patients with multiple myeloma who have previously received and failed, or are intolerant to, treatment with lenalidomide and bortezomib. | Jul 2014 | Recommended with restriction | 175 individuals |
| pomalidomide Treatment in combination with dexamethasone of patients with relapsed and/or refractory multiple myeloma who have received and failed prior treatment with both… | Nov 2014 | Recommended with restriction | none received |
| bortezomib Induction therapy in newly diagnosed symptomatic multiple myeloma patients eligible for high-dose chemotherapy and autologous stem cell transplant, as part of… | Mar 2012 | Recommended with restriction | no section in document |
| bortezomib Induction therapy in patients with newly diagnosed symptomatic multiple myeloma who are eligible for high dose chemotherapy, as part of combination therapy… | Mar 2012 | Recommended | no section in document |
| bortezomib Initial treatment of newly diagnosed symptomatic multiple myeloma patients with severe acute renal failure who require dialysis or are at high risk of… | Jul 2011 | Recommended with restriction | unclear |
| bortezomib First-line treatment of multiple myeloma in patients newly diagnosed with severe renal failure (GFR ≤30 mL/min) or in patients treated with thalidomide who… | Mar 2011 | Recommended | unclear |
| bortezomib First-line treatment of newly diagnosed multiple myeloma patients in combination with melphalan and prednisone (or cyclophosphamide and prednisone) who are… | Mar 2010 | Recommended with restriction | no section in document |
| bortezomib First-line treatment of newly diagnosed multiple myeloma patients who are ineligible for high-dose chemotherapy, in combination with melphalan or… | Mar 2010 | Recommended with restriction | no section in document |
| bortezomib First-line treatment of previously untreated symptomatic multiple myeloma in patients ineligible for high-dose chemotherapy, in combination with melphalan or… | Jul 2009 | Recommended with restriction | unclear |
| thalidomide Extension to current Section 100 listing to include treatment of patients newly diagnosed with multiple myeloma (both those eligible and ineligible for… | Mar 2009 | Recommended with restriction | no section in document |
| doxorubicin hydrochloride, pegylated liposomal Treatment of refractory multiple myeloma in combination with bortezomib in patients who have received at least one prior therapy and who have already undergone… | Jul 2008 | Not recommended | no section in document |
| lenalidomide Treatment of patients with relapsed/refractory multiple myeloma in combination with dexamethasone in patients who have undergone at least one other therapy. | Mar 2008 | Recommended | no section in document |
| lenalidomide Treatment of patients with relapsed/refractory multiple myeloma for whom thalidomide therapy has failed or in whom there is severe intolerance/toxicity to… | Nov 2008 | Recommended with restriction | no section in document |
| bortezomib Treatment of multiple myeloma patients who have failed specified first and second line therapies, have undergone or are ineligible for primary stem cell… | Jul 2007 | Recommended with restriction | no section in document |
| bortezomib Treatment of multiple myeloma in patients who have failed specified prior therapy, have undergone or are ineligible for primary stem cell transplant, and meet… | Jul 2007 | Recommended with restriction | no section in document |
| bortezomib Initial and continuing treatment of multiple myeloma patients who have failed specified prior therapy, with WHO performance status 0-2, who cannot take or are… | Mar 2006 | Not recommended | no section in document |
| bortezomib Initial and continuing treatment of multiple myeloma patients who have failed prior therapy, with WHO performance status 0-2, who cannot take or are failing… | Mar 2006 | Not recommended | no section in document |
| bortezomib Treatment of multiple myeloma in patients with progressive disease, WHO performance status ≤2, who have received at least one prior therapy, and have undergone… | Nov 2006 | Not recommended | no section in document |
| bortezomib Initial and continuing treatment of multiple myeloma patients who have failed specified other therapy, have undergone or are ineligible for a primary stem cell… | Nov 2006 | Not recommended | no section in document |
Who spoke
Myeloma Australia · Leukaemia Foundation · Rare Cancers Australia · South East Myeloma Support Group · Leukemia Foundation · Scientific Group · South-East Myeloma Support Group · Both Myeloma Australia · National Institute · Integrated Clinical Oncology Network
What the PBS pays
$741M in government benefit over 2024–25, across 1,636,779 services.
This is spend on the medicines considered for this condition, not spend on the disease. A medicine used for several conditions is counted in full under each, so figures across conditions add to more than national PBS expenditure.
| Medicine | Government benefit |
|---|---|
| denosumab | $336.2M |
| daratumumab | $225M |
| lenalidomide | $78.7M |
| carfilzomib | $40.1M |
| pomalidomide | $17.6M |
| elotuzumab | $13M |
| bortezomib | $11M |
| selinexor | $8.6M |
| doxorubicin hydrochloride, pegylated liposomal | $6.4M |
| zoledronic acid | $3.7M |
| Thalidomide | $0.4M |
Appraised elsewhere
NICE, in England and Wales, has appraised 41 technologies for this condition, recommending 26 . A different committee, a different population and a different price: this is what has been looked at there, not a verdict on what happened here.
| Technology | Appraisal | Outcome | Date |
|---|---|---|---|
| daratumumabDaratumumab with bortezomib, lenalidomide and dexamethasone for untreated multiple myeloma when a stem cell transplant is unsuitable | TA1170 | recommended restricted | 2026-06 |
| belantamab mafodotinBelantamab mafodotin with bortezomib and dexamethasone for previously treated multiple myeloma | TA1149 | recommended | 2026-04 |
| belantamab mafodotinBelantamab mafodotin with pomalidomide and dexamethasone for previously treated multiple myeloma | TA1133 | recommended | 2026-02 |
| talquetamabTalquetamab for treating relapsed and refractory multiple myeloma after 3 or more treatments | TA1114 | recommended | 2025-12 |
| isatuximabIsatuximab in combination for untreated multiple myeloma when a stem cell transplant is unsuitable | TA1098 | recommended restricted | 2025-09 |
| idecabtagene vicleucelIdecabtagene vicleucel for treating relapsed or refractory multiple myeloma after 2 to 4 treatments (terminated appraisal) | TA1084 | terminated | 2025-07 |
| elranatamabElranatamab for treating relapsed and refractory multiple myeloma after 3 or more treatments | TA1023 | recommended restricted | 2024-12 |
| teclistamabTeclistamab for treating relapsed and refractory multiple myeloma after 3 or more treatments | TA1015 | recommended restricted | 2024-11 |
| selinexorSelinexor with bortezomib and dexamethasone for previously treated multiple myeloma | TA974 | recommended restricted | 2024-05 |
| selinexorSelinexor with dexamethasone for treating relapsed and refractory multiple myeloma after 4 or more treatments | TA970 | recommended | 2024-05 |
| melphalan flufenamideMelphalan flufenamide with dexamethasone for treating relapsed or refractory multiple myeloma (terminated appraisal) | TA968 | terminated | 2024-04 |
| idecabtagene vicleucelIdecabtagene vicleucel for treating relapsed and refractory multiple myeloma after 3 or more treatments (terminated appraisal) | TA936 | terminated | 2023-11 |
Showing the 12 most recent of 41.
Registered, not subsidised
Medicines on the ARTG for this condition with no PBAC record at all. Registration and subsidy are separate decisions: a medicine can be legally available in Australia and never have been put to the committee.
| Medicine | On the ARTG since | Registrations |
|---|---|---|
| melphalanALKERAN INJECTION melphalan 50mg powder for injection composite pack | 1991 | 8 |
| pamidronate disodiumPAMISOL pamidronate disodium 15mg/5mL injection vial | 2000 | 4 |
| talquetamabTALVEY talquetamab 2 mg/mL solution for injection vial | 2024 | 2 |
| isatuximabSARCLISA isatuximab 100 mg/5 mL concentrated injection vial | 2020 | 2 |
The ARTG export holds current registrations only, so the year is the earliest entry still on the register rather than a first-registration date. The condition here comes from the registered label, which is usually broader than the population a sponsor asks to have subsidised.
Conditions are classified by a language model from the indication text of each submission, so an individual label here can be wrong. Consumer input is read from the document's own consumer comments section: 44 of 54 decisions since 2014 carried some. Silence means no comment reached the committee through that facility, not that nobody was affected. More on how this was built.